EssilorLuxottica Société anonyme Valuation
Is EL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EL (€229) is trading below our estimate of fair value (€261.37)
Significantly Below Fair Value: EL is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EL?
Key metric: As EL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is EL's PE Ratio? | |
|---|---|
| PE Ratio | 45.5x |
| Earnings | €2.29b |
| Market Cap | €104.33b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.4x |
| Enterprise Value/EBITDA | 21x |
| PEG Ratio | 2.9x |
Price to Earnings Ratio vs Peers
How does EL's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 27.5x | ||
GBT Guerbet | 10.4x | 18.3% | €341.1m |
BIM bioMérieux | 28.2x | 13.4% | €11.6b |
7741 HOYA | 35.4x | 11.6% | JP¥6.9t |
ALC Alcon | 36x | 9.4% | CHF 37.2b |
EL EssilorLuxottica Société anonyme | 45.5x | 15.6% | €104.3b |
Price-To-Earnings vs Peers: EL is expensive based on its Price-To-Earnings Ratio (45.5x) compared to the peer average (27.5x).
Price to Earnings Ratio vs Industry
How does EL's PE Ratio compare vs other companies in the European Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: EL is expensive based on its Price-To-Earnings Ratio (45.5x) compared to the European Medical Equipment industry average (29.7x).
Price to Earnings Ratio vs Fair Ratio
What is EL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 45.5x |
| Fair PE Ratio | 26.7x |
Price-To-Earnings vs Fair Ratio: EL is expensive based on its Price-To-Earnings Ratio (45.5x) compared to the estimated Fair Price-To-Earnings Ratio (26.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €229.00 | €218.75 -4.5% | 10.3% | €263.00 | €173.00 | n/a | 20 |
| Nov ’25 | €217.00 | €218.75 +0.8% | 10.3% | €263.00 | €173.00 | n/a | 20 |
| Oct ’25 | €211.40 | €212.95 +0.7% | 9.3% | €250.00 | €173.00 | n/a | 19 |
| Sep ’25 | €214.20 | €210.55 -1.7% | 7.9% | €235.00 | €173.00 | n/a | 20 |
| Aug ’25 | €211.00 | €210.05 -0.5% | 8.0% | €235.00 | €173.00 | n/a | 20 |
| Jul ’25 | €201.80 | €209.90 +4.0% | 8.8% | €235.00 | €162.00 | n/a | 20 |
| Jun ’25 | €205.30 | €206.95 +0.8% | 8.2% | €229.00 | €162.00 | n/a | 19 |
| May ’25 | €200.80 | €205.89 +2.5% | 8.2% | €229.00 | €162.00 | n/a | 19 |
| Apr ’25 | €209.70 | €201.16 -4.1% | 7.6% | €228.00 | €162.00 | n/a | 19 |
| Mar ’25 | €197.58 | €197.84 +0.1% | 7.4% | €220.00 | €162.00 | n/a | 20 |
| Feb ’25 | €182.68 | €192.54 +5.4% | 7.5% | €215.00 | €162.00 | n/a | 22 |
| Jan ’25 | €181.60 | €193.26 +6.4% | 8.0% | €220.00 | €162.00 | n/a | 22 |
| Dec ’24 | €178.12 | €193.04 +8.4% | 8.2% | €220.00 | €162.00 | n/a | 22 |
| Nov ’24 | €171.42 | €192.76 +12.5% | 8.2% | €220.00 | €162.00 | €217.00 | 22 |
| Oct ’24 | €165.16 | €194.59 +17.8% | 8.5% | €220.00 | €155.00 | €211.40 | 21 |
| Sep ’24 | €174.18 | €194.15 +11.5% | 8.7% | €220.00 | €155.00 | €214.20 | 20 |
| Aug ’24 | €178.58 | €194.50 +8.9% | 8.7% | €220.00 | €155.00 | €211.00 | 20 |
| Jul ’24 | €172.60 | €192.63 +11.6% | 8.4% | €220.00 | €155.00 | €201.80 | 19 |
| Jun ’24 | €166.60 | €191.94 +15.2% | 8.2% | €215.00 | €155.00 | €205.30 | 18 |
| May ’24 | €179.40 | €191.46 +6.7% | 7.8% | €215.00 | €155.00 | €200.80 | 20 |
| Apr ’24 | €166.00 | €186.01 +12.1% | 8.0% | €210.00 | €155.00 | €209.70 | 19 |
| Mar ’24 | €163.35 | €187.69 +14.9% | 8.4% | €210.00 | €155.00 | €197.58 | 19 |
| Feb ’24 | €168.25 | €187.06 +11.2% | 8.7% | €210.00 | €155.00 | €182.68 | 19 |
| Jan ’24 | €169.20 | €184.66 +9.1% | 9.5% | €210.00 | €150.00 | €181.60 | 20 |
| Dec ’23 | €178.00 | €179.98 +1.1% | 9.0% | €205.00 | €150.00 | €178.12 | 19 |
| Nov ’23 | €161.30 | €179.98 +11.6% | 9.0% | €205.00 | €150.00 | €171.42 | 19 |
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
emeis Société anonyme
€942.5m
Operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals.
EMEIS
€5.86
7D
-9.0%
1Y
-98.8%
LNA Santé
€259.7m
Engages in the management and operation of health establishments.
LNA
€25.40
7D
0.6%
1Y
23.9%
bioMérieux
€11.6b
Develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
BIM
€98.35
7D
-3.9%
1Y
2.6%